A detailed history of Perigon Wealth Management, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Perigon Wealth Management, LLC holds 48,557 shares of BMY stock, worth $2.8 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
48,557
Previous 40,388 20.23%
Holding current value
$2.8 Million
Previous $1.68 Million 49.79%
% of portfolio
0.07%
Previous 0.05%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$39.66 - $51.75 $323,982 - $422,745
8,169 Added 20.23%
48,557 $2.51 Million
Q2 2024

Aug 02, 2024

SELL
$40.25 - $52.99 $70,477 - $92,785
-1,751 Reduced 4.16%
40,388 $1.68 Million
Q1 2024

Apr 29, 2024

SELL
$47.98 - $54.4 $274,445 - $311,168
-5,720 Reduced 11.95%
42,139 $2.29 Million
Q4 2023

Jan 29, 2024

BUY
$48.48 - $57.85 $112,522 - $134,269
2,321 Added 5.1%
47,859 $2.46 Million
Q3 2023

Oct 30, 2023

SELL
$57.89 - $64.73 $596,209 - $666,654
-10,299 Reduced 18.44%
45,538 $2.64 Million
Q2 2023

Aug 02, 2023

BUY
$63.71 - $70.74 $1.87 Million - $2.08 Million
29,337 Added 110.71%
55,837 $3.57 Million
Q1 2023

May 03, 2023

SELL
$65.71 - $74.53 $34,826 - $39,500
-530 Reduced 1.96%
26,500 $1.84 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $639,808 - $757,623
9,343 Added 52.82%
27,030 $1.94 Million
Q3 2022

Dec 13, 2022

SELL
$0.13 - $76.84 $18 - $10,834
-141 Reduced 0.79%
17,687 $1.26 Million
Q2 2022

Aug 11, 2022

BUY
$72.62 - $79.98 $68,335 - $75,261
941 Added 5.57%
17,828 $1.37 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $366,174 - $439,076
5,956 Added 54.49%
16,887 $1.23 Million
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $798,604 - $930,985
-14,891 Reduced 57.67%
10,931 $682,000
Q3 2021

Nov 01, 2021

BUY
$59.17 - $69.31 $1.53 Million - $1.79 Million
25,822 New
25,822 $1.53 Million
Q3 2021

Oct 25, 2021

SELL
$59.17 - $69.31 $1.82 Million - $2.13 Million
-30,744 Closed
0 $0
Q2 2021

Jul 19, 2021

SELL
$61.91 - $67.42 $139,607 - $152,032
-2,255 Reduced 6.83%
30,744 $2.05 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $99,097 - $111,455
1,670 Added 5.33%
32,999 $2.08 Million
Q4 2020

Jan 28, 2021

BUY
$57.74 - $65.43 $230,382 - $261,065
3,990 Added 14.59%
31,329 $1.94 Million
Q3 2020

Nov 03, 2020

SELL
$57.43 - $63.64 $188,025 - $208,357
-3,274 Reduced 10.69%
27,339 $1.65 Million
Q2 2020

Jul 29, 2020

BUY
$54.82 - $64.09 $167,091 - $195,346
3,048 Added 11.06%
30,613 $1.8 Million
Q1 2020

Apr 17, 2020

SELL
$46.4 - $67.43 $61,619 - $89,547
-1,328 Reduced 4.6%
27,565 $1.62 Million
Q4 2019

Jan 13, 2020

BUY
$49.21 - $64.19 $1.07 Million - $1.39 Million
21,690 Added 301.12%
28,893 $1.82 Million
Q3 2019

Oct 25, 2019

SELL
$42.77 - $50.71 $87,892 - $104,209
-2,055 Reduced 22.2%
7,203 $373,000
Q2 2019

Aug 05, 2019

SELL
$44.62 - $49.34 $1,561 - $1,726
-35 Reduced 0.38%
9,258 $420,000
Q1 2019

May 15, 2019

SELL
$45.12 - $53.8 $18,048 - $21,520
-400 Reduced 4.13%
9,293 $428,000
Q4 2018

Feb 11, 2019

BUY
$48.76 - $63.23 $82,892 - $107,491
1,700 Added 21.27%
9,693 $478,000
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $26,215 - $29,568
-475 Reduced 5.61%
7,993 $496,000
Q2 2018

Aug 09, 2018

BUY
$50.53 - $62.98 $3,789 - $4,723
75 Added 0.89%
8,468 $469,000
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $91,078 - $104,849
1,520 Added 22.12%
8,393 $531,000
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $11,988 - $13,069
200 Added 3.0%
6,873 $421,000
Q3 2017

Dec 05, 2017

SELL
$55.23 - $63.74 $319,229 - $368,417
-5,780 Reduced 46.41%
6,673 $425,000
Q2 2017

Sep 12, 2017

BUY
N/A
12,453 New
12,453 $694,000
Q3 2011

Nov 14, 2022

SELL
N/A
-141
17,687 $1.26 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Perigon Wealth Management, LLC Portfolio

Follow Perigon Wealth Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perigon Wealth Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perigon Wealth Management, LLC with notifications on news.